-
Mashup Score: 2
California biotech Bluejay Therapeutics has secured a megaround to continue developing its treatment candidates for chronic hepatitis D and B. The $182 million Series C, disclosed Thursday morning, will bankroll testing of seven programs, including former Novartis and Exicure assets. The biotech’s lead hepatitis asset, BJT-778, derives from Novartis and
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 2After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials - 1 day(s) ago
A half-decade after a scientist’s reckless experiment with human embryos put a stop to much of China’s clinical work on CRISPR gene editing, local researchers are once again performing human studies of the technology. At least three Chinese biotech companies have recently begun tests of CRISPR treatments for blood, eye
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand' - 1 day(s) ago
AstraZeneca is withdrawing its Oxford-collaborated Covid-19 vaccine from global markets, the UK-based pharma company confirmed in a statement to Endpoints News on Tuesday. The spokesperson said AstraZeneca no longer manufactures or supplies the vaccine, which was first cleared for emergency supply in the UK in December 2020 and had since
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1As digital health unicorns are pressured to do more with less, Transcarent gets a fresh $126M - 2 day(s) ago
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Transcarent’s $126 million Series D round, which in May bumped its valuation to $2.2 billion, stands apart from most growth-stage, high-valuation startups that haven’t raised capital in the past few years. While
Source: endpts.comCategories: General Medicine News, Future of MedicineTweet
-
Mashup Score: 2Exclusive: Feng Zhang CRISPR startup gathers patents, locking up rights to family of editing tech - 2 day(s) ago
In the bid to lock up patent rights to a growing suite of gene-editing technologies, Arbor Biotechnologies has acquired a small startup founded by MIT scientist and CRISPR pioneer Feng Zhang, the company exclusively told Endpoints News. Zhang’s startup, Serendipity Bioscience, has never disclosed how much funding it raised, and
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign: getting viruses to work for us, instead of against us. Now, after three years in stealth, Prologue Medicines launched Tuesday morning and unveiled its plan
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Exclusive: New York biotech debuts with $16M to find new ways to make solid cancer cell therapies - 3 day(s) ago
A new biotech is coming out of stealth with $16 million to develop cell therapies for solid cancers — an area where scientists have had limited success. OverT Bio (pronounced
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3
Senate HELP Committee ranking member Bill Cassidy (R-LA) is calling on the Biden administration to do a better job of communicating its findings on the recent outbreak of avian flu among cattle that has infected at least one human. In a three-page letter sent to President Biden on Friday, Cassidy
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 8
Novartis will pay $1 billion upfront to acquire radiopharmaceutical startup Mariana Oncology, just eight months after the preclinical biotech company disclosed a $175 million Series B. The move, which could include another $750 million in milestones, further solidifies the Swiss drug giant’s embrace of the red-hot field of radiopharmaceuticals. Novartis
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
GSK’s vaccines portfolio is front and center as it kicks off 2024. The UK pharma made £7.36 billion ($9.18 billion) in the first three months of the year, with its vaccine products contributing £2.27 billion ($2.83 billion). Its shingles vaccine Shingrix drew £945 million ($1.2 billion) and its RSV product
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
“ goes against the hepatitis B surface antigen, or HBsAg, with the goal of easing immune cell exhaustion so that the body can control the infection. The monoclonal antibody is in a Phase 1/2 test in Australia, New Zealand and other countries.” https://t.co/aGMO79Zwz2